Stocks Screener

Specify Company / Ticker to Get the Summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Dividend History ASND

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Dividend Analytics ASND

Max Ratio

5Y Dividend Growth

Consecutive Years

5Y Average Payout Ratio

Forward Annual Dividend Yield
Consecutive Years
Forward Annual Dividend – USD
Consistent Years
Dividend CAGR 3Y
Continuous Dividends
Dividend CAGR 5Y
Payout Ratio TTM
Dividend CAGR 10Y
Ex Dividend Date

Ascendis Pharma AS

ASND
Current price
176.49 USD +0.77 USD (+0.44%)
Last closed 168.17 USD
ISIN US04351P1012
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 10 536 879 104 USD
Yield for 12 month +30.05 %
1Y
3Y
5Y
10Y
15Y
ASND
21.11.2021 - 28.11.2021

Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Denmark, rest of Europe, North America, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is based in Hellerup, Denmark. Address: Tuborg Boulevard 12, Hellerup, Denmark, 2900

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

232.18 USD

P/E Ratio

Dividend Yield

Financials ASND

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Key Figures ASND

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Current Year

+427 875 864 USD

Last Year

+313 832 034 USD

Current Quarter

+118 786 880 USD

Last Quarter

+204 637 153 USD

Current Year

+375 799 971 USD

Last Year

+261 594 940 USD

Current Quarter

+98 175 614 USD

Last Quarter

+188 137 079 USD
EBITDA -328 827 008 USD
Operating Margin TTM -103.23 %
Price to Earnings
Return On Assets TTM -22.39 %
PEG Ratio
Return On Equity TTM -818.43 %
Wall Street Target Price 232.18 USD
Revenue TTM 368 700 992 USD
Book Value -3.14 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY 5.30 %
Dividend Yield
Gross Profit TTM 314 495 008 USD
Earnings per share -6.86 USD
Diluted Eps TTM -6.86 USD
Most Recent Quarter I 2025
Quarterly Earnings Growth YOY
Profit Margin -92.67 %

Stock Valuation ASND

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 25.11
Price Sales TTM 28.58
Enterprise Value EBITDA -20.75
Price Book MRQ 14.55

Technical Indicators ASND

For 52 Weeks

111.09 USD 183.00 USD
50 Day MA 167.18 USD
Shares Short Prior Month 3 376 040
200 Day MA 146.11 USD
Short Ratio 6.49
Shares Short 2 693 234
Short Percent 5.35 %